TrovaGene Inc TROV shares, which had been on a downtrend since early April, reversed course in mid-August.
From an intraday low of $1.30 on April 14, the stock bounced back and rallied to a high of $3.12 on Monday — a trough-to-peak gain of 140%.
What Drove The Upside
The strong gains came on the back of an announcement from TrovaGene on Thursday, Aug. 15 regarding the presentation of new data from a Phase 2 trial of onvansertib in combination with Zytifa in metastatic castration-resistant prostate cancer, or MCRPC.
The data is set to be presented in an oral moderated poster session at the 20th Asia-Pacific Prostate Cancer Conference at 1 p.m. Australian eastern daylight time on Saturday, Aug. 24.
Source: Y Charts
TrovaGene is developing onvansertib as part of a combination regimen across a variety of cancers and integrating a predictive clinical biomarker strategy to identify patients who are most likely to respond to the treatment.
It is running two Phase 2 trials for onvansertib combo therapies: one in combination with low-dose cytarabine or decitabine for acute myeloid leukemia , and another in combination with Zytiga for mCRPC.
Early Phase 2 data presented at the American Association of Cancer Research in April showed that an early prostate-specific antigen, or PSA, response was observed with the addition of onvansertib to daily abiraterone in two of six patients, with 1 patient achieving the efficacy endpoint of disease control and a 30% decrease in tumor size by RECIST criteria.
"Both patients that showed an early response (at C1D8) with decreases in PSA levels, also tested positive for AR-V7, a highly aggressive androgen receptor variant, which is resistant to Zytiga because it no longer needs androgen for tumor growth," the company said.
Trovagene shares fell 10.49% to $2.56 in Wednesday's session.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
